Cholesterol & Statins

PREVENT — the AHA's 2024 cardiovascular risk calculator

If you've read anywhere on this site that you should "ask your doctor for your PREVENT score" — this is what we're talking about.

What PREVENT is

PREVENT — Predicting Risk of cardiovascular disease EVENTs — is the American Heart Association's 2023/2024 calculator for estimating a person's risk of a major cardiovascular event over the next 10 and 30 years. It is the formal successor to the 2013 Pooled Cohort Equations (PCE) that most US clinicians have been using to decide who qualifies for a statin.

It was derived from contemporary data on more than 6.5 million diverse US adults. It applies to people aged 30 to 79 without known cardiovascular disease. It produces an estimate not just for atherosclerotic events (heart attack, stroke) but for total cardiovascular disease — including heart failure, which the older PCE did not predict at all.[1]

Why it replaced the Pooled Cohort Equations

The 2013 PCE had three increasingly visible problems. First, it included race as a variable — assigning different risk estimates to Black versus White patients with identical clinical profiles, which both clinicians and ethicists came to view as scientifically and morally untenable. Second, it was derived from cohorts collected in the 1960s through 1990s, when smoking was more common and blood pressure control was poorer, which meant it systematically over-estimated cardiovascular event rates for the contemporary US population. Third, it ignored two large drivers of cardiovascular risk that have become better understood in the past decade — kidney function and metabolic health.

PREVENT fixes all three. Race is gone. The training data is contemporary. Kidney function and BMI are now explicit inputs.[2]

What PREVENT asks for

The clinician computing your PREVENT score needs:

Optional add-on inputs that improve precision if available: HbA1c (long-term blood-sugar control), urine albumin–creatinine ratio, social deprivation index.

What PREVENT gives back

Three numbers, each as a percentage:

A clinician then maps your numbers to the relevant guideline's treatment thresholds. The 2018 ACC/AHA cholesterol guideline used 7.5% 10-year ASCVD risk as the threshold for considering statin therapy in primary prevention. The 2024 PREVENT version uses the same numerical threshold — but the same patient will now compute as lower risk than before, because PREVENT is calibrated against contemporary event rates.

What changed in practice

This is the headline finding. When researchers applied PREVENT to the US adult population, it reclassified approximately half of the people who had been considered "statin-eligible" under the 2013 PCE to a lower risk category. The widely reported figure is that around 15.8 million US adults who were nominally candidates for a statin under the old calculator may no longer be under the new one.[3]

For someone in low-to-intermediate primary prevention — no prior cardiovascular event, mid-range cholesterol, decent blood pressure — PREVENT typically returns a risk number 30–40% lower than the old PCE did. That is enough to move a meaningful number of patients from "statin recommended" to "shared decision" or even to "watch and reassess."

This is not because the underlying biology changed. It's because the calibration changed. The old PCE was over-predicting, and we now have the data to know by how much.

What this means for you

The practical implications of PREVENT for a patient sitting with this question — should I be on a statin? — sort into four cases.

1. You've already had a heart attack, stroke, or related event

PREVENT doesn't apply to you. PREVENT is a primary-prevention tool for people without known cardiovascular disease. You're in the secondary prevention bucket where the case for statin therapy is overwhelming and not contested. Skip the calculator; the decision is about LDL target and intensity, not eligibility.

2. You have diabetes, familial hypercholesterolaemia, or LDL ≥ 190 mg/dL

PREVENT will still calculate a number for you, but most guidelines treat these as automatic statin indications regardless of the calculator. The number is informative but doesn't change the recommendation.

3. You're in low-to-intermediate primary prevention

This is where PREVENT changes things most. The right next step is to ask your clinician to compute both your old PCE score and your PREVENT score, and see how big the gap is. If PREVENT moves you below the 7.5% threshold and you have no other strong indication, the conversation legitimately shifts from "let's start a statin" to "let's reassess in 6–12 months and focus on smoking, BP, weight." That is the change PREVENT licenses, and it is a real change in the evidence base, not a preference.

4. You're already on a statin

If you started on the old PCE in a borderline-eligible band and you're now tolerating the drug well, there is no good reason to stop based on the new calculator alone. The new score tells you how aggressively you would now be recommended to start; it does not tell you to stop a therapy that's already working. If you're having side effects or struggling with adherence, that's a different conversation — bring up SAMSON and the rechallenge protocol.

How to use PREVENT before your appointment

PREVENT is intended for clinician use, but the AHA does publish a public-facing calculator. You can plug in your own numbers in advance if you have them.

What to take into the appointment:

  1. Your most recent lipid panel (total cholesterol, HDL, LDL).
  2. Your most recent blood pressure readings, plus what you're on for it.
  3. Your most recent HbA1c (if available) and eGFR (kidney function — also on most blood panels).
  4. Your height and weight (for BMI).
  5. Your smoking status, honestly.

If you can also bring an estimate from both calculators (old PCE and new PREVENT) — many clinicians have not yet switched between them in routine practice, and showing up with both numbers is a faster way to a productive conversation than asking the question abstractly.

Caveats and what PREVENT doesn't do

PREVENT estimates risk; it does not weigh the costs and harms of treatment against that risk. Two patients with identical PREVENT scores can sensibly land on different decisions. The calculator is the input to the decision, not the decision itself.

PREVENT was derived from US adults and applies most cleanly to that population. International applicability is reasonable but imperfect. UK clinicians more often use QRISK3; European clinicians use the ESC's SCORE2. The arithmetic differs; the spirit is the same.

PREVENT is calibrated against current US event rates. If you live somewhere with materially different cardiovascular epidemiology — substantially higher smoking rates, less BP control, different diet patterns — the calibration may be slightly off in your direction. UAE-resident readers: this caveat applies.

PREVENT does not include Lp(a). Lipoprotein(a) is a genetically determined atherogenic particle that 20% of the population has elevated, that standard statins barely touch, and that has three RNA-targeted therapies in late-stage outcome trials (pelacarsen, olpasiran, lepodisiran) reading out between 2025 and 2027. If you have an elevated Lp(a), your true cardiovascular risk is higher than PREVENT alone implies. More on Lp(a) in the synthesis.

PREVENT does not adjudicate the trial-evidence questions about whether statins themselves work in your risk band. It tells you your risk; the decision pathway on this site uses that risk to map you onto the corresponding evidence band from the underlying 267-page synthesis.

Footnotes

  1. Khan SS, Matsushita K, Sang Y, et al. Development and Validation of the American Heart Association's PREVENT Equations. Circulation, 2024. AHA professional summary: professional.heart.org/about-prevent-calculator
  2. AHA newsroom announcement on the removal of race from the equations: newsroom.heart.org/.../leading-cardiologists-reveal-new-heart-disease-risk-calculator
  3. American College of Cardiology summary of the projected statin-eligibility shift: acc.org/.../projected-changes-in-statin

This page is part of the Cholesterol & Statins critical synthesis at articulate-ai.work/statins. Not medical advice. The whole site is open about its limitations — see the external review panel for what it gets wrong.